EDGAR·FLOW

PharmaCyte Biotech, Inc. — Form 8-K

Filed November 19, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
PharmaCyte Biotech (Holder) exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock in Q/C Technologies, Inc. effective November 15, 2026. As majority holder of Q/C's Series H Preferred Stock (3,000,000 shares), PharmaCyte also consented to extend the Series H maturity date by six months from March 2, 2027 to September 2, 2027. PharmaCyte received demand registration rights for resale of the shares.
Why this rating

Major capital deployment: ~4.98M shares received against ~$6.3M PharmaCyte market cap. Increased control through preferred stock leverage and registration rights. Material but not transformational given equity dilution mechanics.

Tradability signal
NO TRADE

No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=592). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$4.56 ▲ 1.79%
at our read · unknown
$4.48
+10 min · unknown
$4.48 ▲ 0.00%
+30 min · unknown
$4.48 ▲ 0.00%
+1 hr · unknown
$4.48 ▲ 0.00%
+4 hrs · unknown
$4.25 ▼ 5.13%

The stock had already moved -1.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PMCB · stock on Yahoo Finance ↗

See more from November 19, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.